Get the Stockscreener App
0.855
10.20%
-0.0921
Palisade Bio Inc stock is traded at $0.855, with a volume of 416.32K.
It is down -10.20% in the last 24 hours and up +37.78% over the past month.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
See More
Previous Close:
$0.9471
Open:
$0.9749
24h Volume:
416.32K
Relative Volume:
1.34
Market Cap:
$4.10M
Revenue:
-
Net Income/Loss:
$-14.07M
P/E Ratio:
-0.0611
EPS:
-13.99
Net Cash Flow:
$-12.56M
1W Performance:
+13.40%
1M Performance:
+37.78%
6M Performance:
-40.52%
1Y Performance:
-80.17%
1-Day Range:
$0.8302
$0.9899
1-Week Range:
$0.72
$0.9899
52-Week Range:
$0.60
$4.65
Palisade Bio Inc Stock (PALI) Company Profile
Name
Palisade Bio Inc
Sector
Industry
Phone
(858) 704-4900
Address
7750 EL CAMINO REAL, SUITE 5200, CARLSBAD
Compare PALI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PALI
Palisade Bio Inc
|
0.855 | 3.82M | 0 | -14.07M | -12.56M | -13.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.08 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.94 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.69 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
568.57 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
292.37 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Palisade Bio Inc Stock (PALI) Latest News
What analysts say about Palisade Bio Inc. stockAccelerated profit realization - jammulinksnews.com
Is Palisade Bio Inc. a good long term investmentPowerful market insights - jammulinksnews.com
Palisade Bio Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference - GlobeNewswire
What drives Palisade Bio Inc. stock priceUnprecedented profits - jammulinksnews.com
What makes Palisade Bio Inc. stock price move sharplyFast Gains With Reduced Risk - Newser
Why Palisade Bio Inc. stock attracts strong analyst attentionBreakout Confirmation Tool - Newser
How Palisade Bio Inc. stock performs during market volatility2x Return Forecast - Newser
Palisade Bio appoints to its Board of Directors - MSN
Palisade Bio appoints Emil Chuang to board of directors By Investing.com - Investing.com Nigeria
Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors - Santé log
Palisade Bio Appoints Emil Chuang as New Director - TipRanks
IBD Drug Development Veteran Joins Palisade Bio Board: 2 FDA Approvals Under His Belt - Stock Titan
Palisade Bio (NASDAQ:PALI) Trading Down 1.8% – Time to Sell? - Defense World
Ulcerative Colitis Drugs Market 2034: Clinical trials, EMA, PDMA, FDA Approvals, Medication, Statistics, Revenue, Therapies, Prevalence and Companies by DelveInsight - Barchart.com
Transpire Bio licenses rights to Intragrand’s PDE4 inhibitor ITG-1052 - BioWorld MedTech
GEN Restaurant Group, Inc. (NASDAQ:GENK) Shares Acquired by Northern Trust Corp - Defense World
Ameriprise Financial Inc. Sells 72,453 Shares of Eni S.p.A. (NYSE:E) - Defense World
The Wharf (Holdings) Limited (OTCMKTS:WARFY) Short Interest Up 27.0% in May - Defense World
Ameriprise Financial Inc. Sells 46,682 Shares of Brookfield Renewable Co. (NYSE:BEPC) - Defense World
Invesco S&P SmallCap Health Care ETF (NASDAQ:PSCH) Shares Purchased by Ameriprise Financial Inc. - Defense World
Yankuang Energy Group Company Limited (OTCMKTS:YZCAY) Short Interest Up 25.0% in May - Defense World
BOE Varitronix Limited (OTCMKTS:VARXF) Short Interest Update - Defense World
U.S. Global Jets ETF (NYSEARCA:JETS) Shares Sold by Ameriprise Financial Inc. - Defense World
Riverside Resources (OTCMKTS:RVSDF) Stock Price Down 9.3% – Should You Sell? - Defense World
Clune & Associates LTD. Invests $7.30 Million in Apple Inc. (NASDAQ:AAPL) - Defense World
5,157 Shares in Aligos Therapeutics, Inc. (NASDAQ:ALGS) Bought by Northern Trust Corp - Defense World
Northern Trust Corp Raises Holdings in Key Tronic Co. (NASDAQ:KTCC) - Defense World
Ameriprise Financial Inc. Purchases New Position in Quantum Computing Inc. (NASDAQ:QUBT) - Defense World
Cetera Investment Advisers Purchases Shares of 70,006 Palisade Bio, Inc. (NASDAQ:PALI) - Defense World
Nuvation Bio’s (NUVB) “Market Outperform” Rating Reaffirmed at JMP Securities - Defense World
Ameriprise Financial Inc. Boosts Stake in BlackRock California Municipal Income Trust (NYSE:BFZ) - Defense World
Northern Trust Corp Acquires New Shares in iShares 10-20 Year Treasury Bond ETF (NYSEARCA:TLH) - Defense World
Torrid Holdings Inc. (NYSE:CURV) Shares Purchased by Bank of America Corp DE - Defense World
TPI Composites, Inc. (NASDAQ:TPIC) Shares Acquired by Bank of America Corp DE - Defense World
Palisade Bio Reports Improved Quarterly Losses - TipRanks
BNP Paribas Financial Markets Increases Position in Community West Bancshares (NASDAQ:CWBC) - Defense World
Palisade Bio (PALI) Reports Positive Phase 1 Results for PALI-21 - GuruFocus
Palisade Bio reports positive Phase 1 results for new drug By Investing.com - Investing.com South Africa
Palisade Bio Reports Positive Topline Data From Phase 1 Studies Of PALI-2108 - Nasdaq
Palatin Technologies (PALI) Teams Up with Key Managers for Inves - GuruFocus
Palisade Bio (PALI) Reports Positive Phase 1 Results for PALI-2108 | PALI Stock News - GuruFocus
Palatin Technologies (PALI) Teams Up with Key Managers for Investment Strategy | PALI Stock News - GuruFocus
Digital Ally, Inc. Sets Date to Discuss First Quarter 2025 Earnings Call Wednesday, May 28, 2025 at 11:15 a.m. Eastern Time - The Manila Times
Palisade Bio reports positive Phase 1 results for new drug - Investing.com
Palisade Bio Reports Positive Phase 1a Results for - GlobeNewswire
Breakthrough in Crohn's Disease Treatment: New Drug PALI-2108 Achieves Perfect Safety Profile in Phase 1 Trial - Stock Titan
Seneca Biopharma : Announces Update on Phase II Clinical Trial Underway in China for the Treatment of Ischemic Stroke - marketscreener.com
Palisade Bio Inc Stock (PALI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Palisade Bio Inc Stock (PALI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Wei Binxian | Director |
Nov 21 '24 |
Option Exercise |
0.00 |
388 |
0 |
855 |
0.20%
0.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):